In the pathogenesis of CML, pro-inflammatory cytokines, including IL-6, IL-1β, and TNF-α, are upregulated in the serum [103], and this “pro-inflammatory environment” may promote a selective advantage for LSCs. Here, IL6 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.